CTLA-4 and PD-1 are immune checkpoint inhibitors that have been identified as antibody immunotherapy targets for the treatment of melanoma, and the combination of CTLA4 and PD-1 was shown to significantly improve the survival of patients with metastatic melanoma.[39–42] The analysis of combinations of antiPD-1 and antiCTLA-4 also revealed that the low m6Ascore group showed a higher positive response to antiPD-1 therapy and combination therapy of antiCTLA4 and antiPD-1. This evidence concerns the gene CTLA4 and melanoma.